[Infliximab-induced hepatitis in a patient with Crohn's disease].
Soto-Fernández
S
S
González-Carro
P
P
De Pedro-Esteban
A
A
Legaz-Huidobro
M L
ML
Pérez-Roldán
F
F
Roncero García-Escribano
O
O
Valbuena-González
M
M
Ruiz-Carrillo
F
F
D000208:Acute Disease; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D003131:Combined Modality Therapy; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy* / Q000628:therapy; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D007937:Leukapheresis; D019804:Mesalamine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D010195:Pancreatitis / Q000139:chemically induced; D011241:Prednisone / Q000627:therapeutic use; D012006:Rectovaginal Fistula / Q000188:drug therapy / Q000209:etiology
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D019804:Mesalamine; D000069285:Infliximab; D001379:Azathioprine; D011241:Prednisone; D008727:Methotrexate